ozempic eli lilly news - Search News

Lilly Cements Weight Loss Lead

Reuters on MSN · 2d

In weight loss battle, Novo and Lilly face growing offensive from licensed copies

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented remedies are winning approval from some regulators overseas, posing a threat to the pharma giants' prices and market share.

CNN on MSN · 1d

Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late-stage clinical trial findings reported Friday.

Bloomberg on MSN · 1d

Lilly Cements Weight Loss Lead After Novo Trial Setback

The fierce battle between weight-loss drug makers has led to sky-high Wall Street expectations, with investors anticipating new medicines that are incrementally more powerful and easier to take.

Novo Nordisk raises expectations for Eli Lilly

Hosted on MSN · 2d

Novo Nordisk Stock Crashes More Than 20% After Disappointing Obesity Drug Data. Eli Lilly Shares Soar.

Novo Nordisk stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and Wegovy, posted disappointing clinical trial data for its experimental obesity drug CagriSema.

The Motley Fool · 2d

Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

CNBC on MSN · 1d

Novo Nordisk: Why the stock of the Danish pharmaceutical giant is plunging

Emily Field, Barclays head of European pharmaceutical research, joins CNBC's 'The Exchange' to discuss why Novo Nordisk shares are falling, the competition in the weight-loss drug space, and more.

2d

Ozempic MDL Expands to Include New Drugs, but Not New Injuries

"An MDL that encompassed any potential injury relating to use of these exceedingly popular weight loss drugs might quickly ...

3d

This Is Huge News for Eli Lilly Investors

Eli Lilly just gave investors several reasons to cheer.

2d

Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now

The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...

Daily Journal2h

Lilly stock caught up in wave of uncertainty

Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...

FDA reaffirms decision to erase Eli Lilly's tirzepatide from shortage list, halting future flow of knockoffs

The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...

Bloomberg L.P. on MSN3d

Lilly’s US Weight-Loss Drug Shortage Ends, Curtailing Copies

Eli Lilly & Co.’s diabetes and weight-loss drugs Mounjaro and Zepbound are no longer in short supply in the US, which ...

EU reportedly reviewing link between Ozempic, rare eye disease

With U.S. headquarters in Plainsboro, Novo Nordisk told NJBIZ, "NAION is a very rare eye disease, and it is not an adverse ...

2don MSN

FDA says knockoff versions of Lilly obesity drug must come off the market

Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and ...

2d

Ozempic lures people to the doctor, Nestle's GLP-1 'shot,' an FDA Zepbound ruling: Pharma news roundup

Nestle just rolled out a new protein shot drink that it says will help people looking to lose weight manage their hunger and ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results